Tc-99m sestamibi and In-111 pentetreotide uptake in metastatic papillary thyroid carcinoma.
Approximately 25% of metastatic and recurrent differentiated (papillary and follicular) thyroid carcinoma do not concentrate 1-131 Nal. In such cases, diagnosis can be attempted with other radiopharmaceuticals. The authors present a case of recurrent papillary thyroid carcinoma that was well visualized with Tc-99m sestamibi and In-111 pentetreotide; but only poorly visualized by I-131 Nal.
Lee
J
J
Department of Radiology, Medicine Harbor-UCLA Medical Center, Torrance 90509, USA.
Cutrone
J A
JA
Marcus
C S
CS
D000368:Aged; D000369:Aged, 80 and over; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging* / Q000556:secondary*; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D017256:Technetium Tc 99m Sestamibi; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*
D007205:Indium Radioisotopes; D017256:Technetium Tc 99m Sestamibi